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Abstract
Background: Although people with cancer want and need information from their oncologists,
patients and oncologists often disagree about what information was discussed during clinical
interactions. Most patients have companions present during oncology visits; we investigated
whether companions process information more accurately than patients. Specifically, we exam-
ined whether patients and companions differed in agreement with oncologists about what was
discussed. We also investigated the effect of topic on agreement and patient/companion self-
reported understanding of discussions.
Methods: Patients with companions were invited to participate on first visits to a cancer
center in Detroit, MI. Patients, companions, and oncologists independently completed question-
naires immediately following visits. Participants were asked whether five topics were discussed
(diagnosis, prognosis, metastasis, treatment/treatment goals, and side effects) and, if discussed,
what oncologists said. Participants were also asked to estimate their own and each other’s
understanding of discussions.
Results: A total of 66 patient–companion–oncologist triads participated. Agreement was
higher regarding whether topics were discussed than what oncologists said. Agreement did
not differ by dyad type. Patients, companions, and oncologists were equally likely to be the
source of triadic disagreements. Agreement was high about diagnosis (>90%) but much lower
about other topics, particularly side effects. Patients and companions reported greater under-
standing of discussions than oncologists estimated and more accurately estimated each other’s
understanding than did oncologists.
Conclusions: Companions and patients showed similar levels of agreement with oncologists
about what they discussed during visits. Interventions are needed to improve communication
of information to both patients and companions, especially about particular topics.
Copyright © 2012 John Wiley & Sons, Ltd.
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Introduction
Most people with cancer want as much information
as possible during cancer interactions [1,2], and their pre-
ferred information source is a physician or other health
care provider [3–6]. Exchanging information effectively
during cancer clinical interactions is associated with posi-
tive outcomes for patients [1,5,7–9]. This complex com-
munication process, however, is only effective to the
extent that patients and physicians agree about what infor-
mation they discussed and have a shared understanding
of key aspects of discussions [10–12]. Ineffective infor-
mation exchanges can leave patients confused, dissatis-
fied, and potentially ill-prepared to make appropriate
decisions and fully participate in their care [8,9,13–17].
Unfortunately, patients with cancer often disagree
with their oncologists about what they discussed during
their clinical visits, and levels of agreement vary based
on the topic under discussion [15,18–20]. For example,
patients and oncologists generally agree on whether
they discussed a patient’s diagnosis, but are less likely
to agree on other topics, such as treatment goals and
side effects. This disagreement may be, in part, related
to patients’ difficulty in processing information accu-
rately and efficiently due to high levels of cancer-
related anxiety and distress [21,22]. Thus, having a
companion present in the interaction may be helpful
to patients, especially during initial meetings with an
oncologist.
In fact, many patients have a companion with them
when they see their physicians, particularly if they are
older, sicker, and less educated [23,24]. Research shows
companions provide a benefit during clinical visits by
providing social and emotional support to patients and
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facilitating some aspects of information exchange
between patients and physicians, such as asking ques-
tions and providing information [12,24–28]. Possibly,
companions facilitate information exchange during
cancer visits in other ways as well. Relative to patients,
companions may experience less cancer-related anxiety
and distress and are thus better able to accurately process
information discussed with oncologists. If this is true,
companions should show greater agreement with oncol-
ogists about what was discussed than patients and thus
potentially serve as an important resource to patients as
they make decisions and take actions related to their care.
Another possibility is that patient–oncologist dis-
agreement about what information was discussed is re-
lated to oncologists’ difficulties in communicating
complex, high-stakes information clearly and effec-
tively, rather than patients’ inability to process informa-
tion. If this is true, patients and companions should show
comparable levels of agreement with oncologists about
what was discussed, and companions may be less able
to serve as a resource to patients following clinical visits.
To investigate these two possibilities, we examined
relative levels of objective agreement about (a) whether
a topic was discussed and (b) the content of the discus-
sion (i.e., what the oncologist said about the topic)
between and among patients (P), companions (C), and
oncologists (O) in triadic clinical interactions. We also
examined whether the topic being discussed affected
agreement. Additionally, we examined relative levels
of patient and companion self-reported understanding
of information discussed and compared them with the
other participants’ estimates of their understanding.
Findings from this study may inform the develop-
ment of interventions to improve communication in this
context. If companions show greater agreement with
oncologists about what information was discussed
during clinical visits than the patients they accompany,
interventions should be designed to promote the role of
companions in the interactions. On the other hand, if
companion–oncologist agreement is similar to patient–
oncologist agreement, interventions should be designed
to improve the way cancer health information is
discussed with both patients and their companions.
Participants and methods
Participants
We conducted this study in the multidisciplinary outpa-
tient clinic of the Karmanos Cancer Center, a National
Cancer Institute-designated comprehensive cancer
center in Detroit, MI, from May to August 2009. The
Institutional Review Board at Wayne State University
approved all study procedures. Oncologists who pri-
marily treated solid tumors (N= 8) were asked to partic-
ipate if they regularly saw new patients in the clinic
where recruitment occurred; all 8 agreed to participate.
Oncologists provided blanket consent to recruit their
eligible patients. English-speaking patients of these
oncologists were recruited immediately following their
first visit if they had a companion with them who was
present during the visit.
Measures
Oncologists, patients, and companions independently
completed questionnaires about five topics routinely
discussed during initial cancer clinical interactions:
cancer diagnosis, prognosis, metastasis, treatment/
treatment goals, and side effects. The patient question-
naire is presented in Table 1; companion and oncologist
questionnaires were adapted accordingly. Questionnaires
were administered immediately after the visit to ensure
participants did not communicate with each other or any-
one else prior to completing them. In the first section of
the questionnaire, participants were asked if each topic
was discussed; if they responded affirmatively, they were
also asked about the content (i.e., what the oncologist
said about the topic). The only major difference in
questions about topic and content was that participants
were first asked if treatment was discussed (topic); if
Table 1. Patient questionnaire
Please read the questions below and answer them as best you can. These
questions are only about your visit with the doctor today.
Part I
Diagnosis
1. Did the doctor tell you what your medical problem is or give you a diagnosis
today? _Yes _No (If you answered no, you do not need to continue.)
It is definitely cancer.
It is probably cancer.
It is probably not cancer.
It is definitely not cancer. (If you circled this one, go to Part II)
2. Did your doctor tell you how serious your cancer is? _Yes _No (If you
answered No, go to Question #4.)
The doctor said my cancer can definitely be cured.
The doctor said my cancer can probably be cured.
The doctor said my cancer cannot be cured.
The doctor did not say if my cancer can be cured.
3. Did your doctor discuss whether your cancer has spread to other places in
your body? _Yes _No (If you answered No, go to Question #4.)
The doctor is sure the cancer has spread.
The doctor is sure the cancer has not spread.
The doctor is not sure if the cancer has spread.
Treatment
4. Did the doctor recommend a treatment for your cancer?
_Yes _No
The treatment is to cure the cancer.
The treatment is to improve the cancer so that I can have another treatment
to cure the cancer.
The treatment probably will not cure the cancer, but it can reduce the
symptoms so that I am more comfortable.
5. Did the doctor discuss or mention any side effects of the treatment?
_Yes _No
They are moderately serious.
They are mild.
They are very mild.
Part II (scale: 1 = not at all; 4 = extremely well)
1. How well do you think you understand what the doctor told you today
about . . .
(a) Your medical problem or diagnosis?
(b) Your treatment?
2. How well do you think your companion understands what the doctor told you
today about. . .
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they responded affirmatively, they were asked about
treatment goals (content). As the questionnaire instruc-
tions show, skip patterns were used. For example, if
participants reported the topic diagnosis was discussed,
they were also asked about the content (i.e., what the
oncologist said about diagnosis). However, if they said
diagnosis was not discussed, they were instructed to skip
all remaining questions and were not included in any
further analyses. This and other skip patterns resulted in
substantially different sample sizes for each analysis.
In the second section, patients and companions used a
four-point scale (1 = ‘not at all’ to 4 = ‘extremely well’)
to rate their own and the other participant’s (i.e., patient
or companion) understanding of what the oncologist
said about diagnosis and treatment. Using the same
scale, oncologists were asked to estimate patients’ and
companions’ understanding of these two topics. All par-
ticipants also provided socio-demographic information.
Analysis
We conducted either multiple regressions (for continu-
ous outcomes) or logistic regressions (for dichotomous
outcomes) using general estimating equations (GEE)
to assess associations among the variables of interest.
GEE was employed because patients and companions
were nested within oncologists. GEE provides consis-
tent and asymptotically normal estimates regardless of
how strongly observations within groups are correlated
with one another [29]. In the logistic regression analyses,
the topic ‘diagnosis’ was not included because partici-
pants agreed almost perfectly on this topic and thus no
variability was observed. Where appropriate, contin-




One hundred and fifty new patients were identified
during the study period. Sixty-two were not approached
for the following reasons: they were unaccompanied
(n=36), were deemed by the oncologist to be too ill or
overwhelmed to be approached (n=21), or did not speak
English (n=5). Of the 88 remaining patient–companion
dyads, 66 (75%) agreed to participate and comprise the
final sample. Thus, the maximum number of dyads in
each analysis was 198 (i.e., three per interaction) and
the maximum number of triads was 66 (one per interac-
tion). If one member of a dyad/triad did not answer a
question, the dyad/triad was not included in the analyses.
Most of the oncologists were men (87.5%); half self-
identified as White and the others as either Asian or
Middle-Eastern. The majority (75%) had practiced for
over 6 years (post-fellowship) at the cancer center.
Oncology specialties included breast, gastrointestinal,
genitourinary, thoracic, and malignant hematology. All
but one oncologist participated in multiple interactions
(range 1–17).
Patient and companion demographics are reported in
Table 2. Patients were older than companions (p< 0.05),
had higher levels of education (p< 0.001), and were
more likely to be male (p< 0.01). Most companions
were spouses (56.1%). None of the patients’ and
companions’ socio-demographic characteristics were
significantly associated with the indices of agreement/
disagreement or self-reports of understanding.
Dyadic and triadic agreement about whether topics
were discussed
Dyads
Figure 1 shows percent agreement for each dyad type
(P–O, C–O, and P–C) about whether topics were dis-
cussed. Overall, 81.3% of dyads agreed about whether
topics were discussed. In general, participants were
more likely to agree that topics were discussed rather
than were not discussed. An analysis of differences in
agreements across the three dyad types showed that
average agreement for P–O was 81.7% (range: 100%
for diagnosis to 62% for side effects); for C–O, 78.8%
(range: 98.5% for diagnosis to 64.5% for prognosis);
and for P–C, 83.5% (range: 98.5% for diagnosis to
74.6% for prognosis).
The GEE logistic regressions showed no significant
differences among dyad types in overall percent agree-
ment; in other words, companion–oncologist and
patient–oncologist agreements were equivalent. How-
ever, regressions of four topics (excluding diagnosis
because of absence of variance) revealed significant
differences among topics in overall percent agreement.
Specifically, the average percent agreement for side
effects (70.8%) was significantly lower than for
Table 2. Patient and companion characteristics
Characteristics Patients (n=66) Companions (n=66)
Mean age (SD) 58.6 (12.5) 54.6 (10.1)
Gender
Male 34 (51.5%) 18 (27.3%)
Ethnicity (Missing = 1)
Caucasian 50 (76.9%) 50 (75.8%)
African American 11 (16.9%) 15 (22.7%)
Asian 3 (4.6%) 1 (1.5%)
Other 1 (1.5%) —
Marital status (Missing = 1)
Married 46 (70.8%) 52 (78.8%)
Divorced 4 (6.2%) 5 (7.6%)
Widowed 5 (7.7%) 3 (4.5%)
Domestic partner 1 (1.5%) 1 (1.5%)
Never married 9 (13.8%) 5 (7.6%)
Annual household income ($) (Missing = 6) (Missing = 9)
Less than 10,000 5 (8.3%) 5 (8.8%)
10,000–19,999 9 (15.0%) 5 (8.8%)
20,000–39,999 13 (21.7%) 10 (17.5%)
40,000–59,999 7 (11.7%) 6 (10.5%)
60,000–100,000 14 (23.3%) 18 (31.6%)
Greater than 100,000 12 (20.0%) 13 (22.8%)
Education (Missing = 2) (Missing = 1)
Some high school 27 (42.2%) 24 (36.9%)
Some college 18 (28.1%) 29 (44.6%)
Graduate/professional school 19 (29.7%) 12 (18.5%)
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metastasis (84.3%; b=1.06, SE= 0.33, w²(1) = 10.65,
p< 0.001) and for treatment (80.6%; b=0.56, SE=0.26,
w²(1) = 4.64, p< 0.05). There was no difference in the
average percent agreement between side effects and
prognosis (72.0%; p = 0.60).
Finally, we examined the joint effects of dyad and
topic on agreements about whether topics were dis-
cussed. We found no significant differences among
dyad types when topics were analyzed individually.
Triads
Across the five topics, triadic agreement about whether
each topic was discussed was 72.2% (Table 3). Triadic
agreement was greatest for diagnosis (98.5%, n= 65)
and lower for prognosis (59.7%, n= 62), metastasis
(75.0%, n= 36), treatment (70.8%, n = 65), and side
effects (57.1%, n = 42).
We examined which participant was the source of
triadic disagreements. Of the 72 triadic disagreements
across topics, oncologists were the source of 38.9% of
disagreements, companions 38.9%, and patients 22.2%.
A goodness-of-fit chi-square, comparing these percen-
tages, was not significant (w²(2) = 4.00, ns).
Finally, we considered the joint effects of triad mem-
ber and topic on patterns of triadic agreement. Compa-
nions were most frequently the source of triadic
disagreements for prognosis (44.0% of 25 disagree-
ments, where a disagreement is the sum of non-gray
cells in Table 3) and treatment (52.6% of 19 disagree-
ments). Oncologists were most frequently the source
of disagreements for side effects (55.6% of 18 disagree-
ments). However, chi-square analyses of disagreement
patterns were not significant. That is, a uniform distri-
bution of 33% disagreements for each triad member
could not be rejected.
Dyadic and triadic agreement about the content of
discussions
The analyses that follow are based on the subset of cases
in which both dyad and all triad members agreed that a
topic had been discussed and responded to questions
about the content of discussions. We recorded parti-
cipants’ choices into dichotomized outcomes (e.g.,
‘definitely’ and ‘probably’ cancer were recorded as
‘cancer’; ‘probably not’ and ‘not’ cancer were recorded
as ‘not cancer’). Thus, in the analyses that follow, agree-
ment does not necessarily reflect exact agreement from
among the alternative responses.
Dyads
Figure 2 shows percent agreement for each dyad type
(P–O, C–O, and P–C) about the content of topics dis-
cussed. Overall, 62.3% of dyads agreed about content.
Agreement for P–O was 58.3% (range: 93.4% for diag-
nosis to 37.5% for side effects); for C–O, 59.3%
(range: 98.3% for diagnosis to 30.4% for side effects);
and for P–C, 69.1% (range: 91.9% for diagnosis to
48.9% for treatment goals).
Consistent with findings for whether topics were dis-
cussed, logistic regressions revealed no significant dif-
ferences in percent agreement by dyad type; again,
companion–oncologist and patient–oncologist agree-
ments regarding content were comparable. Logistic
regressions for the four topics (again excluding diagno-
sis) did reveal significant differences in percent agree-
ment as a function of the content of the topics. Again,
consistent with findings for whether topics were dis-
cussed, percent agreement on the content of side effects
discussions (43.2%) was significantly lower than prog-
nosis (59.8%; b =1.91, SE= 0.48, w²(1) = 15.82,
p< 0.001) and metastasis (67.5%; b=0.82, SE=
0.32, w²(1) = 6.75, p< 0.01). However, there was no
difference between side effects and treatment goals
(59.8%; p= 0.38).
Finally, we considered the joint effects of dyad type
and topic on agreement about content. We found that
for side effects, P–C agreement was significantly higher
than agreement for both P–O (b = 1.21, SE= 0.58,
w²(1) = 4.35, p< 0.05) and C–O (b = 1.62, SE= 0.59,
w²(1) = 2.77, p< 0.01) agreement. There were no differ-
ences in agreement by dyad type for prognosis, metas-
tasis, or treatment goals.
Triads
Across the five topics, 73.8% of triads agreed on con-
tent (Table 4). Agreement was highest for diagnosis
(98.3%, n= 59), followed by prognosis (94.7%, n= 9),
metastasis (76.0%, n= 5), treatment goals (50.0%,
n= 28), and side effects (50.0%, n= 22).
An examination of the source of triadic disagree-
ments about content showed that, of the 33 disagree-
ments across topics, oncologists were the source in
45.5% of the disagreements, patients in 30.3%, and
companions in the remaining 24.2%. A goodness-of-
fit chi-square, comparing these percentages, was not
significant (w²(2) = 2.36, ns).
Finally, we considered the joint effects of triad mem-
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content. For treatment goals, patients were most fre-
quently the source of disagreements (42.9% of 14 dis-
agreements), but for side effects, oncologists were most
frequently the source (72.7% of 11 disagreements); the
latter pattern is significantly different from a uniform
distribution (w²(2) = 8.91, p< 0.01). There was no clear
source of disagreements for the other topics. Given the
very small number of disagreements about some topics,
both null and significant findings must be interpreted
with caution.
Self-reported and estimated understanding of
patients’ and companions’ understanding of
information
Table 5 presents means/standard deviations for patients’
and companions’ self-reports of their understanding of
discussions of diagnosis and treatment and the other
triad members’ estimates of patients’ and companions’
understanding. Patients reported significantly more
understanding of diagnosis than treatment (p< 0.001);
there was no such difference for companions. Oncolo-
gists’ estimates of both patients’ and companions’ un-
derstanding were invariably lower than patients’ and
companions’ self-reports and their estimates of one
another’s understanding.
Table 3. Patterns of triadic agreement about whether topics were discussed
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As shown in Table 5, across all four GEE regressions,
there were significant positive associations between
patients’ and companions’ estimates of one another’s
understanding of diagnosis and treatment. In contrast,
the regression weights for the oncologists’ estimates
were non-significant in three of the equations and
significant and negative in the equation involving
patients’ understanding of diagnosis. However, the
significance of this regression weight may reflect a form
of cooperative suppression [30] rather than a simple
negative bivariate association. The bivariate association
between oncologists’ and companions’ estimates of
patients’ understanding, while also negative, was actu-
ally small and non-significant (r=0.08).
Discussion
Patients and oncologists often disagree about what
information they discussed during cancer interactions
and potentially misunderstand key aspects of their
Table 4. Triadic agreement and disagreement in the content of topics discussed
Cases in which all three members agreed are highlighted in gray. N= number of triads for each topic.
Table 5. Patients’ and companions’ self-reported understanding
of topics discussed and participants’ estimates of patient and
companion understanding
Understanding N M SD b
Patient diagnosis 65 3.69 0.53
Companion estimate 66 3.50 0.59 0.43**
Oncologist estimate 65 3.34 0.78 0.33*
Patient treatment 62 3.44 0.62
Companion estimate 64 3.41 0.64 0.30*
Oncologist estimate 63 3.11 0.79 0.00
Companion diagnosis 65 3.60 0.63
Patient estimate 65 3.52 0.62 0.46**
Oncologist estimate 65 3.25 0.77 0.12
Companion treatment 62 3.63 0.52
Patient estimate 63 3.40 0.61 0.39**
Oncologist estimate 63 3.08 0.79 0.17
Regression coefficients indicate the association between patient/companion self-
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discussions [15,18–20,22]. Prior research shows many
patients have a family member or other companion with
them in the interactions and that these companions im-
prove some aspects of communication, by, for example,
asking questions on behalf of patients [23,24,26,28]. We
investigated whether companions also process informa-
tion more accurately than patients in this setting. We
compared companion–oncologist and patient–oncologist
agreements about what information was discussed
during triadic clinical interactions. We also investigated
whether the topic under discussion (i.e., diagnosis,
prognosis, metastasis, treatment/treatment goals, and
side effects) affected levels of agreement and patient
and companion self-reported understanding of topics
discussed.
We found levels of agreement across dyads in these
clinical interactions to be relatively high (approximately
82%) with regard to whether a topic was discussed,
but lower regarding the content of discussions (approx-
imately 62%). However, agreement did not differ by
dyad type; in other words, companion–oncologist
agreement was no higher than patient–oncologist
agreement. Further, the source of disagreements within
triads was fairly evenly distributed across patients,
companions, and oncologists. These findings suggest
companions’ processing of information in this setting
is no more accurate than patients’.
Consistent with prior research [15,18–20], our
findings showed the topic under discussion influenced
agreement. Participants generally agreed on whether
diagnosis was discussed and, if discussed, what the
oncologist said. Possibly, agreements were high about
diagnosis because these interactions occurred in a
cancer center, where presumably patients arrive having
already received a diagnosis of cancer. Alternatively, if
patients received a diagnosis for the first time during
these interactions, their reaction to the news may have
inhibited their ability to accurately process information
about other topics discussed later in the visit. In fact,
participants were much less likely to agree about other
topics, particularly side effects. A clear understanding
of these topics is critical to patients’ willingness and
ability to adhere to treatment recommendations. Thus,
these findings suggest the need for improvement in
the communication of information about most cancer
topics.
We did not audio-record or video-record the interac-
tions and thus could not determine which participant
was objectively ‘accurate.’ Clearly, such information
is valuable in analyses of patient–physician communi-
cation. However, this study focused on assessing agree-
ment in participants’ beliefs about what was discussed,
rather than on comparing their beliefs with the assess-
ment of external raters. It is participants’ beliefs about
what was discussed that influence decisions about treat-
ment, and differences in these beliefs that may lead to
confusion, dissatisfaction, and poorer care.
Finally, we found that patients’ and companions’
estimates of each other’s self-reported understanding
were more accurate than oncologists’ estimates of
patients’ and companions’ understanding. As mentioned
previously, we measured perceived understanding rather
than actual comprehension and thus cannot speculate as
to the accuracy of any participant’s perception. However,
this finding suggests oncologists are less attuned to
patients’ and companions’ levels of understanding than
patients and companions are of each other’s. This is not
surprising given patients’ and companions’ ongoing
relationship. More surprising is that the oncologists
underestimated, rather than overestimated, patients’ and
companions’ perceived understanding. Possibly, this
finding indicates that oncologists are aware of the diffi-
culties inherent in meeting the complex, high-stakes
informational needs of both patients and companions in
this setting. This finding, then, also suggests that inter-
ventions are needed to improve the way information is
discussed with both patients and companions.
Although we collected data in a cancer center provid-
ing care to a diverse population of patients, we found no
significant differences in agreement or understanding
by patient socio-demographic characteristics. This is
surprising given other research showing racial differ-
ences in the quality of communication in oncology
interactions [25,28,31,32]. In a separate analysis of
these data, we found that oncologists were significantly
less likely to discuss side effects with Black patients
than withWhite patients [33] (suggesting another aspect
of the difficulties related to discussing side effects). The
present study included relatively few Black patients, in
part because they were more often unaccompanied than
Whites and thus were ineligible. Thus, analyses of
Black–White differences were generally underpowered,
which could result in null findings for racial differences.
We acknowledge several other potential limitations.
We did not assess non-English-speaking patients or
those whose oncologists deemed them too ill or over-
whelmed to participate. Patients and oncologists were
more likely to be male, whereas companions were more
likely to be female, which may have resulted in some
residual gender effects. Future studies assessing triadic
interactions would benefit from recruiting a larger and
more diverse sample of patients. Future studies might
also compare patient–oncologist agreement following
clinical interactions in which patients are accompanied
and unaccompanied.
Taken together, our findings suggest the potential for
ineffective communication even when patients bring
companions to clinical visits. Interventions are needed
to improve this critically important aspect of patient
care [34]. Some oncologists are ineffective communi-
cators and can improve their skills through better train-
ing and modeling [35–38]. Others are highly skilled
communicators, but the task of discussing complex,
high-stakes information with patients and families is
daunting [39]. One solution may be to have nurses,
health educators, or patient advocates routinely present
during clinical interactions and available to continue
discussions as needed. By being present during clinical
interactions with oncologists, these providers may be
viewed as endorsed by oncologists. They could thus
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be an integral part of the longer-term information ex-
change process, reducing the potential for miscommu-
nication that may occur if information is provided in
disjointed or fragmented conversations across health
care providers. Another suggestion is to provide audio
recordings or written summaries of consultations,
which may benefit patients and also companions not
present during visits [40]. These types of interventions
have the potential to improve care for all patients,
whether or not companions are present during clinical
interactions.
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